An innovative postbiotic for people with osteoarthritis and joint and mobility disorders.  

Arthelio® is an innovative postbiotic for people with osteoarthritis and joint and mobility disorders.  

Did you know that a leaky gut can play a role in the inflammation and even degradation of cartilage? 

Supported by 30 years of academic research and 5 years of product development, Arthelio® is the first microbiotic innovation for people with osteoarthritis and joint/mobility disorders. 

Why choose Arthelio®?

Arthelio® is the first microbiotic innovation in joint health, and is backed by decades of research. 

  • Supported by 30 years of academic research 
  • 5 years of product development 
  • Unique and patented innovation for people with osteoarthritis and joint/mobility disorders 

Innovation backed by 30 years of scientific research

If there is an imbalance in the gut, then more bacteria may penetrate the intestinal wall. This results in more pro-inflammatory molecules in the blood, which trigger the immune system and consequently cause inflammation in the joints. This is know as the gut-joint axis. It is this inflammation which leads to the cartilage degradation that affects people with osteoarthritis. 

How does Arthelio® help?

  • Harnesses the power of B. longum lysate (CBi0703®) and vitamin C in synergy to help improve mobility, comfort and quality of life. 
  • Vitamin C contributes to collagen formation, healthy cartilage and normal joint functionality. 
  • Lysate of B. longum CBi0703® helps prevent bacteria from going through the intestinal wall and consequently reduces inflammation in the joints.  

Science supporting Arthelio®

Arthelio® is effective at reducing joint discomfort and improving ability to carry out day-to-day physical activities   

Adami G, 2023 evaluated the effects of taking Arthelio® on pain management, stiffness and the ability to perform normal physical activities3.  


  • 44 patients diagnosed with osteoarthritis of the knees or hips. 
  • Study participants completed questionnaires to objectively evaluate symptoms and joint function before and after taking Arthelio® for 90 days 


  • Marked improvement in symptoms after 90 days of treatment 
  • Reduced pain and stiffness. Less difficulty with daily physical activities and improved quality of life

Osteoarthritis sufferers reported fewer, shorter, and less painful flare-ups after Arthelio® supplementation, reducing their need for painkillers and medication

Breban M and Henrotin Y, 2020 conducted a survey of consumers with numerous and painful flare-ups4.


  • 320 subjects aged 25-65 and suffering from osteoarthritis, took Arthelio® for 3 months.  
  • Studied criteria included: frequency and length of flare-ups, pain intensity, loss of movement, quality of life, drug intake. 
YEAR 2020
DURATION 3 months
POPULATION 320 subjects
Age: 25-65 years old
Diagnosed with osteoarthritis
DOSAGE 1 capsule per day
METHODOLOGY Telephone questionnaire conducted before and after supplementation reporting frequency and length of flare-ups, pain intensity, loss of movement, quality of life, drug intake.


After taking Arthelio® for 3 months, participants reported: 

  • Fewer flare-ups 
  • Reduced pain intensity during flares 
  • Improved knee mobility 
  • Significant reduction in painkiller and anti-osteoarthritis drug use 
  • Some benefits were observed right from the first month of treatment 
  • 1 month after stopping Arthelio® treatment, pain and functional limitations return 
  • Resuming Arthelio® treatment for 1 month reactivates most of the benefits  
  • No side effects reported 

Arthelio® has no known side effects and no known interactions


Arthelio® is a food supplement containing: 

  • 25 mg of Bifidobacterium longum CBi0703® freeze-dried inactivated culture 
  • 90 mg of vitamin C 

Available in capsule form for adults and in bulk premix form. 


1 capsule a day for 3 months to be renewed as necessary 

Regulatory and certifications

This solution is unique and patented.

  • Ingredient manufactured under GMP Pharma rules. 
  • The product Arthelio® complies with the CE regulation 1169/2011 
  • Non-GMO, gluten-free 

Why choose ABbiotek Health?

  • We provide tailored microbiome solutions to address specific health challenges including Digestive, Immunity and Mobility disorders.
  • We’re dedicated to providing a natural-first option to complement conventional drugs.
  • Our teams of experts use proven fermentation technology to get bacteria, yeasts, and enzymes (BYE) working in synergy to produce innovative ingredients for the pharma, medical nutrition, food, nutraceutical and pet care industries. 
  • We have an advanced supply chain infrastructure which gives us the ability to service customers across the globe


1. Huang ZY, Stabler T, Pei FX, Kraus VB. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthritis Cartilage. 2016 Oct;24(10):1769-1775. doi: 10.1016/j.joca.2016.05.008. Epub 2016 May 20. PMID: 27216281; PMCID: PMC5026878.
2. Henrotin Y, Patrier S, Pralus A et al. Protective Actions of Oral Administration of Bifidobacterium longum CBi0703 in Spontaneous Osteoarthritis in Dunkin Hartley Guinea Pig Model. Cartilage 2019: 1947603519841674. doi: 10.1177/1947603519841674.
3. Adami G. Bifidobacterium longum CBi0703® e vitamina C in pazienti con gonartrosi e coxartrosi. Giornale Italiano di Ortopedia e Traumatologia 2023;49:195-202;
4. Breban M and Henrotin Y. L’arthrose: La piste du microbiote vers un nouveau paradigme? Rhumatos 2020, 17(157) :2 


This website is intended to provide information about ABbiotek Health’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.